Immature and unstable tumor vasculature provides an aberrant tumor microenvironment and leads to resistance of tumors to conventional therapy. Hence, normalization of tumor vessels has been reported to improve the effect of immuno-, chemo-and radiation therapy. However, the humoral factors, which can effectively induce maturation of tumor vasculature, have not been elucidated. In this study, we found that the novel peptide apelin and its receptor APJ can induce the morphological and functional maturation of blood vessels in tumors. This apelin-induced tumor vascular maturation enhances the efficacy of cancer dendritic cell-based immunotherapy and significantly suppresses tumor growth by promoting the infiltration of invariant natural killer T cells into the central region of the tumor and thereby robustly inducing apoptosis of tumor cells. Additionally, we showed APJ expression to be enhanced in the tumor endothelium in comparison with normal-state endothelial cells. These findings provide a new target for tumor vascular-specific maturation, which is expected to improve the efficacy of conventional cancer therapies.
Introduction
Agents targeting the tumor vasculature have been used for antitumor therapy in various preclinical and clinical studies (Gasparini et al., 2005; Heath and Bicknell, 2009) . The function of vascular endothelial growth factor (VEGF)-family ligands and their receptors in tumor angiogenesis has been well established, and serves as a logical target for antiangiogenic cancer therapy (Lohela et al., 2009) .The anti-VEGF monoclonal antibody, bevacizumab, neutralizes all isoforms of human VEGF (Gerber and Ferrara, 2005) . Combining bevacizumab with chemotherapeutic agents appears to result in modest survival benefit in patients with metastatic colorectal cancer (Hurwitz et al., 2004) . This antitumor effect of bevacizumab was assumed to be due to its disruption of VEGF, and it was expected to directly suppress endothelial cell (EC) growth and inhibit tumor angiogenesis. However, Jain and co-workers recently showed that anti-angiogenic therapy causes 'normalization' of aberrant tumor vasculature and thus induces the formation of functional mature vasculature (Jain, 2005) . This normalization of the tumor vasculature is effective for combination antitumor therapies, because mature vasculature and increased blood flow to tumors can promote the delivery of antitumor therapeutics to tumor cells (Dickson et al., 2007) . Therefore, investigating the role played by endogenous vascular maturation factors during the angiogenesis process could help in the development of a new antitumor therapy.
Apelin, a secreted peptide, has been identified as the endogenous ligand of the G-protein-coupled cell-surface receptor APJ (Tatemoto et al., 1998) . Apelin and APJ mediate a wide range of physiological actions, including angiogenesis (Cox et al., 2006; Eyries et al., 2008; Kasai et al., 2008; Kidoya et al., 2008) , heart contractility, blood pressure regulation (Dai et al., 2006) and other effects (Sorhede Winzell et al., 2005; Lambrecht et al., 2006; Lago et al., 2007) . Apelin and APJ are expressed on ECs of newly developing blood vessels during angiogenesis (Kidoya et al., 2008) , and it has been reported that apelin expression is induced by hypoxia in ECs (Eyries et al., 2008) . In vitro analyses revealed that apelin stimulates the proliferation, migration and tube formation of ECs (Kasai et al., 2004; Masri et al., 2004) . Recently, we reported that apelin-deficient mice have narrow blood vessels, but in contrast, apelinoverexpressing mice have enlarged blood vessels. Apelin induces larger cords of ECs, mainly mediated by cell-cell aggregation, resulting in the formation of enlarged blood vessels (Kidoya et al., 2008) . These enlarged blood vessels are stable, and vascular permeability was reduced (Kidoya et al., 2010) . Taken together, these data support the notion that the apelin/ APJ pathway has an important role in vascular maturation, especially for regulating the caliber of blood vessels to facilitate lumen enlargement (Kasai et al., 2008; Kidoya et al., 2008) .
Invariant natural killer T (iNKT) cells are implicated in the control of autoimmunity (Singh et al., 2001) , resistance to tumors (Shin et al., 2001; Smyth et al., 2002) and protection against infectious agents (Kakimi et al., 2000) . The iNKT cells are characterized by the co-expression of natural killer (NK) receptor and T-cell receptor (TCR), which is encoded in humans by Va24-JaQ gene segments and in mice by homologous Va14-Ja281 sequences (Taniguchi et al., 2003) . iNKT cells are activated by a specific glycolipid antigen a-galactosylceramide (aGalCer) presented on CD1d (Kawano et al., 1997; Brossay et al., 1998; Spada et al., 1998) . Activated iNKT cells also induce cell death in tumor cells by the expression of a wide variety of cell death-inducing effector molecules, including perforin, Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand, in a manner similar to other cytotoxic cells such as NK cells and CD8 cytotoxic T cells (Nieda et al., 2001) . Furthermore, activation of iNKT cells induces a rapid release of cytokines, including interleukin-4, interleukin-12 and interferon-g (IFN-g) (Smyth et al., 2002) .
We previously reported that intravenous injection of aGalCer-pulsed dendritic cells (DCs) induced the activation of murine iNKT cells in vivo, and eradicated established metastatic tumor foci in models of mouse liver and lung metastasis (Shin et al., 2001) . Based on these observations in murine models, several clinical trials of intravenous injection of aGalCer-pulsed DCs have been performed (Nieda et al., 2001; Motohashi et al., 2009) . In these studies, the interventions had limited clinical efficacy in advanced cancer patients, although iNKT cell-specific systemic immune responses had been induced in a large population of the patients. We hypothesized that optimal delivery of effector cells to the target tissues is necessary to improve the efficacy of this immunotherapy. Therefore, we performed a clinical trial using intra-arterial infusion of activated iNKT cells for patients with advanced head and neck cancer , and a significant tumor reduction was observed in some patients after direct infusion of iNKT cells to the tumor-feeding arteries.
In the present study, we analyze the expression and function of the apelin-APJ system in the tumor vasculature and examined the therapeutic effects of apelin-mediated tumor vascular normalization. Moreover, we also studied the effects of combination therapy with tumor vascular normalization by apelin and cancer immunotherapy by activated DC transplantation in the mouse tumor model.
Results

Apelin and APJ are highly expressed in tumor ECs
We previously reported temporal expression of APJ in ECs during angiogenesis in embryos and during the process of recovery from ischemic states (Kidoya et al., 2008 (Kidoya et al., , 2010 . To determine whether apelin and APJ are expressed in a cell type-specific manner in ECs of tumor vessels, we evaluated the expression of vascular apelin and APJ in growing syngeneic mouse tumors by realtime PCR and immunohistochemical analyses. In realtime PCR analysis, we used CD31 þ CD45À ECs obtained from the heart, skin or tumors of mice by fluorescence-activated cell sorting sorting. Compared with normal tissue ECs, APJ was more highly expressed in ECs from colon26 murine colon adenocarcinoma and Lewis lung carcinoma (LLC) (Figure 1a) .
Immunohistochemical analysis of tumor tissue derived from colon26 murine colon cancer revealed that apelin and APJ are specifically expressed in the tumor vasculature (Figures 1b and c) . Apelin and APJ expression was not observed in all tumor vessels, but about 13% of vessels were APJ-positive and about 27% of vessels were apelin-positive (Figure 1d) . By analyzing the relationship between location or caliber of vessels and APJ expression, many APJ-positive ECs were observed in the large-caliber blood vessels in the peripheral region (Figure 1e ). We also detected apelin and APJ protein expression in LLC tumor tissue blood vessels by immunohistochemical staining (Figures 1f  and g ). In these tumors, most ECs co-expressed apelin and APJ as reported previously (Ka¨lin et al., 2007) (data not shown). These data indicated that apelin and APJ are highly expressed in tumor blood vessels.
Apelin induces blood vessel enlargement in tumors and inhibits tumor growth
To analyze the effects of apelin on the morphology of blood vessels, we first observed the growth of blood vessels in tumors. Colon26 mouse colon cancer cells stably transfected with the apelin expression vector ( Figure 2a) were inoculated under the skin of BALB/c mice to form tumors. Overexpression of apelin greatly inhibited the growth of colon26 tumors in all three cell lines derived from distinct clones (Figure 2b ). In agreement with a previous report that apelin induced enlarged blood vessels in the dermis of apelin Tg mice (Kidoya et al., 2010) , the caliber of blood vessels observed in tumors formed by colon26 cells transduced with apelin was enlarged compared with control colon26 tumors (Figures 2c-e) . This enlargement of tumor vessels is not dependent on tumor size, because the lumen size of the vessels was different even for tumors of the same volume (300 mm 3 ) (Supplementary Figure 1 ; day 8 for colon26/vector, day 10 for colon26/apelin). However, there is little difference between density of blood vessels in apelin-expressing tumor and control tumor (date not shown). Blood vessel enlargement by apelin was also observed in tumors developed from PC3 human prostate cancer cells (Figures 2f-h ) and B16 mouse melanoma cells (data not shown). This indicated that the action of apelin on the change in the caliber of blood vessels is not a specific response to colon26 cells.
It is well known that the size of newly developed blood vessels is affected by mural cell adhesion to ECs during the maturation process of blood vessel formation (Gerhardt and Betsholtz, 2003) . Usually, the blood vessels observed in tumors are not well covered with mural cells. In order to determine whether apelin is involved in muscularization resulting in enlargement of blood vessels, tumor sections were stained with an antismooth muscle actin antibody. As shown in Figure 2i , the preexisting vessels around tumor were well muscularized, but mural cells did not adhere to the ECs of enlarged blood vessels in colon26 tumors expressing apelin. This suggested that the induced enlargement of blood vessels by apelin occurs independently of mural cells.
Apelin induces the formation of functional, non-leaky, mature vessels Recent reports indicate that anti-angiogenic cancer therapy often converts the immature blood vessels in tumors to more a normal functional vascular network (Jain, 2005; Dickson et al., 2007) . As shown Figure 2b , apelin-mediated maturation of the tumor vasculature suppressed tumor growth. Therefore, we examined whether the apelin-induced enlargement of blood vessel also contributes to functional blood vessel normalization. Because the tumor vasculature is generally immature and leaky, oxygen cannot reach the center of the tumor tissue, leading to hypoxia. However, the hypoxic status of the center of tumor tissues was moderated in the tumors formed by the colon26 cells transduced with apelin (Figures 3a and b) . Moreover, fluorescence-conjugated 100 mM dextran effectively infiltrated to the center of tumor tissues in apelinexpressing colon26 tumors (Figures 3c and d) . These results indicate that the apelin-mediated enlargement of tumor vessels also induced the functional maturation of the blood vessels.
We then analyzed the phenotype of the CD31 þ CD45À ECs isolated from apelin-expressing or control colon26 tumors. In the apelin-transduced tumors, the expression level of EC-related genes VCAM1, Flk1, Flt1 and APJ was increased (Figures 3e and f) . Furthermore, consistent with our previous report, expression of the EC junction proteins VE-cadherin and Claudin5 was upregulated ( Figure 3f ). Therefore, we speculated that the increased vascular stability observed in the apelinexpressing tumors is due to these changes in the EC phenotypes.
Functional analysis of aGalCer-pulsed mature BMDCs Tumor vessel vascular normalization has been reported to enhance the therapeutic effects of anticancer drugs, radiotherapy and immunotherapy (Willett et al., 2006) . Therefore, we examined whether induction of functional normalization of blood vessels induced by apelin improved the efficacy of cancer immunotherapy. In addition, we hypothesized that vascular normalization would improve the migration of antitumor effector cells to the tumor site. Furthermore, we believed that Apelin improves immunotherapy by vessel maturation H Kidoya et al effector cell-mediated cancer immunotherapy, combined with vascular normalization, would demonstrate more significant antitumor effects than either treatment alone. iNKT cells are a very small cell population in the peripheral blood before stimulation with aGalCer, a specific glycolipid antigen (Kawano et al., 1997; Brossay et al., 1998; Spada et al., 1998) . After activation, the iNKT cell population significantly expands and exerts strong antitumor activity against various malignant tumors both in vivo and in vitro (Kawano et al., 1999; Shin et al., 2001; Seino et al., 2005) . Therefore, we investigated the synergistic effects between vascular normalization with apelin and immunotherapy with aGalCer-pulsed DCs whose antitumor response had already reported in mice and humans (Nieda et al., 2004; Kunii et al., 2009; Motohashi et al., 2009) .
Prepared aGalCer-pulsed or vehicle-pulsed mature bone marrow (BM)-derived DCs (BMDCs) were analyzed by flow cytometry after 8 days of culture. Both groups of BMDCs highly expressed CD11c (83%) and major histocompatibility complex (MHC) class-II (about 95%); moreover, the expression levels of CD86 and CD80 were also high (60-90%) (Figure 4a ). These cells were injected into mice on day 0 and then the number of peripheral iNKT cells was monitored. The iNKT cell populations were significantly elevated on day 4 in mice injected with aGalCer-pulsed BMDCs (Figure 4b ). Alternately, peripheral iNKT cell numbers remained at low levels in mice injected with vehiclepulsed DCs. Therefore, we used both sets of DCs for antitumor immunotherapy experiments.
Enhancement of antitumor effects by combination of apelin stimulation and DC treatment
To evaluate the synergistic effect of apelin-mediated normalization of the tumor vasculature and immu- Figure 2) . Therefore, after implantation of colon26/ vector or colon26/apelin cells into the subcutaneous tissue of mice, mature DCs were administered by intravenous injection on day 4 and tumors were harvested on day 14 (Figure 5a ). We observed antitumor effects, as described previously, in the apelin-expressing tumor or in vector-transduced colon26 tumors treated with aGalCer/DCs, but more remarkable antitumor effects were observed in mice that underwent both apelin transduction and DC treatment (Figures 5b-d) . Growth of colon26/apelin tumors treated with aGalCer/DCs slowed when tumor volumes exceeded 100 mm 3 (Figure 5b ). The tumor weight of colon26/apelin tumors treated with aGalCer/DCs was exceedingly small and comprised only about a fourth of the vehicle/DCs-treated, apelintransduced colon26 tumors or aGalCer/DCs-treated, vector-transduced colon26 tumors (Figures 5c and d) . These data suggest that the vascular normalization induced by apelin markedly improved the effects of immunotherapy.
To exclude the possibility that apelin activated the immune cells and enhanced their antitumor effect, we analyzed the expression of APJ in iNKT cells and DCs. Compared with tumor blood vascular ECs, APJ expression in iNKT cells and in each of the DCs was extremely low and almost undetectable, respectively (Figure 5e ). Therefore, apelin is not likely to directly activate these cells.
Infiltration of iNKT cells into tumor tissues was promoted by apelin-induced vascular maturation Finally, to confirm that the antitumor effect observed in the colon26/apelin tumors treated with aGalCer/DCs was actually caused by iNKT cell infiltration into tumor tissue or activation induced by the DCs, we analyzed tumor tissues, which were harvested 14 days after tumor cell inoculation. We observed higher levels of NKp46 þ cell infiltration in aGalCer/DC-treated colon26/apelin tumors as compared with colon/vector tumors and 
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IFN-g production in response to aGalCer antigenic stimulation was increased in peripheral blood cells of mice treated with aGalCer/DCs (Figure 6d ). Moreover, many apoptotic tumor cells were observed in aGalCer/ DC-treated colon26/apelin tumors (Figures 6e and f) . These results suggest that the potent antitumor effects observed in aGalCer/DC-treated colon26/apelin tumors was caused by enhanced infiltration of iNKT cells in the center of the tumor tissue, thus inducing apoptotic tumor cell death.
Discussion
We found that expression of APJ (the apelin receptor) was significantly increased in tumor blood vessels and apelin simulation induced enlargement of the caliber of tumor vessels. Enlargement of tumor vessels by apelin also led to functional maturation and normalization, including suppression of vascular permeability and improvement of oxygen supply to the central tumor.
Normalization of the tumor vasculature induced by VEGF-neutralizing antibodies has been reported to suppress tumor growth (Kim et al., 1993) . In our study, apelin-induced vascular maturation also demonstrated an antitumor growth effect. One of the major therapeutic benefits of tumor vascular normalization is enhancement of the effects of conventional cancer therapy such as chemotherapy, radiotherapy and immunotherapy. In our present study, we used a combination of immunotherapy with DC treatment with vascular normalization therapy due to apelin expression and obtained remarkable antitumor effects. These therapeutic effects resulted from induction of tumor cell apoptosis by effective infiltration of activated iNKT cells.
Several researchers have reported that apelin is relevant to blood vessel formation not only under physiological conditions, but also in a neoplastic context (Seaman et al., 2007; Sorli et al., 2007) . Consistent with these results, we found that apelin expression was observed in vascular ECs of colon26 tumors and LLC tumors. In addition, we revealed that APJ expression was also upregulated in these tumor ECs. Our previous 
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H Kidoya et al report showed that APJ expression was induced by VEGF stimulation of ECs of blood vessels where angiogenesis is taking place (Kidoya et al., 2008) .We predict that APJ expression in tumor blood vessels is also regulated by the same mechanism, because angiogenesis is frequently observed in tumor tissues. Of interest, APJ-expressing angiogenic ECs are almost imperceptible in healthy adults. Although apelin has been reported to act on heart contractility and blood pressure regulation, apelin-deficient and apelin-overexpressing mice show normal growth after birth (Kidoya et al., 2008 (Kidoya et al., , 2010 . Therefore, anti-angiogenesis drugs targeting apelin would be expected to have fewer side effects than other anti-angiogenic agents targeting more ubiquitously expressed molecules such as VEGF. We previously reported that apelin regulates the lumen size of the blood vessels of embryos during the vascular maturation process. In this report, we found that the tumor vasculature is also regulated by apelin stimulation. Blood vessels in tumors are functionally immature and characteristically leaky in nature (Bergers and Benjamin, 2003) . From analysis of blood vessels in the skin of apelin-overexpressing mice, it was apparent that apelin can enhance vascular stability and suppress vascular permeability (Kidoya et al., 2010) . In the tumor vessels examined in our present study, we found that apelin improved stability and induced normalization by upregulating the expression of adhesion molecules in ECs.
Tumor blood vessels are structurally and functionally abnormal, and these abnormalities impair the tumor oxygen supply (Padera et al., 2004) . The hypoxic microenvironment formed in this manner induces genetic instability and leads to further alterations in malignant cells (Bottaro and Liotta, 2003) . The vascular normalization induced by a VEGF-neutralizing antibody can alleviate the hypoxic condition of the tumor microenvironment and suppress malignant transformation. Apelin stimulation also improved the function of tumor blood vessels and alleviated the hypoxia. We attributed the growth suppression of the apelin-expressing tumors observed in this study to this effect. It is possible that tumor vessels normalized by apelin enhance the delivery of nutrients to tumor cells. However, this vascular normalization might also induce an antitumor effect by immunocyte infiltration, because the concentration of apoptotic tumor cells was increased in the colon/apelin þ vehicle group as compared with the colon/vector þ vehicle group, as shown in Figure 6f .
Contrary to our results, it has been reported that apelin induces tumor angiogenesis and promotes tumor growth (Sorli et al., 2007) . This difference might depend on the particular apelin-APJ signaling pathway that has been activated, such as the angiopietin1-Tie2 signaling pathway (Fukuhara et al., 2008) . The apelin-APJ system activates the Akt and ERK (extracellular-signal regulated kinase) signaling pathways, which might be involved in vascular stabilization and pro-angiogenesis, respectively. Therefore, apelin may have a beneficial effect in cancer treatment, if it can be predicted before treatment in individual cases that apelin induces normalization of the tumor vasculature.
Current immunotherapy for human solid cancers can be classified into the following categories (Rosenberg et al., 2008) : one is non-specific immunomodulation, such as interleukin-2 therapy for renal cancer or metastatic melanoma (Rosenberg et al., 1989) . Another is use of a cancer vaccine containing tumor peptides or DCs (Steinman and Banchereau, 2007) that activates the patient's immunity against their cancer. The last category is adoptive cell transfer, in which in vitro expanded autologous antitumor effector cells are administered to the patient (Rosenberg et al., 2008) . In all of these treatments, effector cell delivery to the tumor site is indispensable, and therefore, improvements in delivery would increase the therapeutic effects of all of these approaches. In this study, we used the DC therapy targeted to iNKT cells because tumor-infiltrating cells can be specifically evaluated. There are few iNKT cells at the tumor site before stimulation, and significant expansions of iNKT cells were observed after activation with the unique antigen. Based on these findings, it was strongly expected that combination with vascular normalization therapy would also improve the efficacy of the other immunotherapy such as tumor antigenspecific T-cell therapy. Therefore, as a follow-up study, we are preparing to examine combination treatment by adoptive cell transfer using engineered T lymphocytes (June et al., 2009) , and the difference in infiltration into the tumor site between iNKT cells and conventional T cells will be assessed.
Induction of vascular normalization leads to enhancement of the efficacy of conventional therapies (Willett et al., 2006) . Here we have demonstrated that combination therapy using vascular maturation induced by apelin and immune therapy with administration of antigen-loaded DCs remarkably suppressed the growth of colon26 tumors. This antitumor effect was attributed to dramatic infiltration of DC-activated iNKT cells and subsequent induction of apoptosis in the tumor cells. It was recently reported that inhibition of angiogenesis lead to normalized endothelial adhesion molecule levels and improves tumor growth inhibition by promoting leukocyte extravasation (Dings et al., 2011) . Upregulation of VCAM1 expression was also induced in the endothelium of apelin-expressing tumor, and it would promote iNKT cell infiltration. Tumor vascular normalization induced by apelin therefore appears to augment immunotherapy as well as chemotherapy and radiotherapy.
In summary, our data suggest that vascular normalization induced by apelin can enhance the effect of immunotherapy by promoting immune cell recruitment. Many angiogenic factors have been identified, and their functions have been described, and many of these factors have been or are being targeted as new cancer therapy approaches. Compared with these angiogenic molecules, apelin has a unique function in that it regulates blood vessel maturation, but has limited functions with regard to induction of angiogenesis. In addition, apelin-targeting agents would have fewer side effects, because expression of the apelin receptor, APJ, is confined to newly formed blood vessels such as tumor vessels. Induction of tumor vascular normalization by recombinant apelin administration is difficult because the apelin peptide is unstable. For these reasons, the design of drugs that target the apelin-APJ system, such as more stable and potent APJ receptor agonist, is expected to provide novel agents that by regulating the tumor vasculature will introduce an effective new cancer treatment.
Materials and methods
Mice C57BL/6 mice, KSN nude mice and BALB/c mice at 8 weeks of age were purchased from Japan SLC (Shizuoka, Japan) and were used between 8 and 12 weeks of age. The animals were housed in environmentally controlled rooms of the animal experimentation facility at Osaka University. All experiments were performed in compliance with the laws and institutional guidelines of Osaka University.
Cells
Cell lines, including colon26, PC3 and LLC, were purchased from RIKEN cell bank (Tsukuba, Japan). The culture medium used was RPMI-1640 containing 10% fetal calf serum, 50 mM 2-mercaptoethanol, 2 mM glutamine and 10 mM HEPES buffer. DCs were grown from bone marrow progenitors in culture medium supplemented with 20 ng/ml recombinant murine granulocyte-macrophage colony-stimulating factor (eBioscience, San Diego, CA, USA) (Fujii et al., 2002) . On day 6, aGalCer (100 ng/ ml; Kyowa Hakko, Gunma, Japan) was added to immature BMDCs for 40 h. To induce maturation of the DCs, 100 ng/ml lipopolysaccharide (Wako, Osaka, Japan) was added on day 7 for 16 h. Mature aGalCer-pulsed DCs were collected on day 8.
Tissue preparation, immunohistochemistry and flow cytometry Tissue fixation and staining of sections with antibodies were performed as described previously (Takakura et al., 2000) . An anti-CD31 monoclonal antibody (mAb) (BD Biosciences, San Diego, CA, USA), anti-a-smooth muscle actin mAb (Dako, Glostrup, Denmark), anti-apelin mAb (4G5) (Kawamata et al., 2001) , anti-APJ polyclonal Ab (Kidoya et al., 2008) and an anti-NKp46 mAb (R&D Systems, Minneapolis, MN, USA) were used for staining. TUNEL (TdT-mediated dNTP nick end labeling) assays were performed using the ApopTag Plus kit (Millipore, Billerica, MA, USA). Sections were observed by conventional microscopy (DM5500 B; Leica, Wetzlar, Germany) or confocal microscopy (TCS/SP5; Leica), and images were acquired with a digital camera (DFC500; Leica). In all assays, an isotype-matched control Ig was used as negative control and it was confirmed that the positive signals were not derived from nonspecific background. Images were processed using the Photoshop CS2 software (Adobe Systems, San Jose, CA, USA). Flow-cytometric analysis was performed as described previously (Yamada and Takakura, 2006) . Fluorescence-labeled anti-CD45, anti-CD31, anti-CD86, anti-MHC class-II, anti-TCR-b, anti-CD1d, anti-CD80, antiCD11c antibody (BD Biosciences) and CD1d tetramer antibodies (Proimmune, Oxford, UK) were used. Stained cells were analyzed with a FACSCalibur (BD Biosciences), by using the FlowJo software (TreeStar, Ashland, OR, USA), and sorted by using a JSAN flow cytometer (Bay Bioscience, Kobe, Japan). Dead cells were excluded from propidium iodide staining or analyses using the two-dimensional profile of the forward versus side scatter.
Real-time PCR analysis
Total RNA was extracted by using the RNeasy plus kit (Qiagen, Hilden, Germany) and reverse-transcribed into cDNA using the ExScript RT-PCR kit (Takara, Otsu, Japan). The primer pairs used for analysis are listed in Supplementary  Table 1 . Real-time PCR analysis was performed by using Platinum SYBR-Green SuperMix-UDG (Invitrogen, Carlsbad, CA, USA). The levels of PCR products were monitored with an Mx3000P QPCR system (Agilent, Santa Clara, CA, USA). Baseline and threshold were adjusted according to the manufacturer's instructions. The relative abundance of transcripts was normalized to the constitutive expression level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA.
Tumor growth assay
The mouse Apelin gene was cloned into the pCAGSIH expression vector (Kidoya et al., 2008) . Colon26 cells and PC3 cells were stably transfected by using the Lipofectamine Plus reagent (Invitrogen) and clones of cells showing stable transfection were obtained by antibiotic resistance selection using G418 (Gibco, Grand Island, NY, USA) and hygromycin-B (Sigma, St Louis, MO, USA). The stably transfected colon26 clones (1 Â 10 6 cells), PC3 clones (1 Â 10 7 cells) or LLC cells (3 Â 10 6 cells) were inoculated subcutaneously into 6-to 8-week-old BALB/c mice, nude mice or C57BL/6 mice, respectively, and tumors were dissected at 12-15 days after implantation. DCs (6 Â 10 5 cells) were administered by intravenous injection 4 days after tumor implantation. To measure hypoxia in tumor tissues, HypoxyProbe-1 (Millipore; 60 mg/kg) was injected intraperitoneally 1 h before killing. Tumors sections were stained using an anti-HypoxyProbe antibody. To evaluate macromolecule infiltration, mice were intravenously injected with fluorescein isothiocyanate-conjugated dextran (500 mg; Vector Laboratories, Burlingame, CA, USA) and dextran was circulated for 10-30 min.
ELISpot assay IFN-g-producing cells were analyzed with a mouse IFN-g ELISpot kit (Mabtech AB, Stockholm, Sweden). Peripheral blood mononuclear cells (5 Â 10 5 per well, 96-well plates) were stimulated by addition of 100 ng/ml aGalCer or vehicle. Concanavalin-A was used as a positive control. IFN-g spotforming cells were quantified objectively by using an ImmunoScan computer system and the ImmunoSpot software program (CTL, Cleveland, OH, USA).
Statistical analysis
All data are presented as the means±s.d. For statistical analysis, the statcel2 software package (OMS, Saitama, Japan) was used, with analysis of variance performed on all data, followed by the Tukey-Kramer multiple comparison test. When only two groups were compared, a two-sided Student's t-test was used.
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